- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Leerink cuts Stryker stock price target to $407 on model update | 6 | Investing.com | ||
| Fr | The Stryker Attack Shows Growing Gaps in Mobile Device Security | 13 | The Fast Mode | ||
| Di | Stryker launches new small bone power tool for orthopedic procedures | 7 | MassDevice | ||
| Mo | Is Stryker Stock Underperforming the S&P 500? | 10 | Barchart.com | ||
| 29.05. | Hedge Fund and Insider Trading News: Ken Griffin, Michael Burry, Bill Ackman, Warren Buffett, Voss Capital, Cinctive Capital Management, Stryker Corp (SYK), Twilio Inc (TWLO), and More | 35 | Insider Monkey | ||
| 29.05. | Director Of Stryker Sold $96.79M In Stock | 25 | Benzinga.com | ||
| 28.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 28.05.2026 | 290 | Xetra Newsboard | The following instruments on XETRA do have their first trading 28.05.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.05.2026
Aktien
1 CZ0009008819 Karo Leather a.s.
2... ► Artikel lesen | |
| 26.05. | Stryker bringt das Pangea-Plattensystem auf den Markt und schließt den ersten Eingriff in Europa ab | 503 | Business Wire | Stryker (NYSE:SYK), ein weltweit führendes Unternehmen im Bereich Medizintechnik, gab heute die Markteinführung seines Pangea-Plattensystems in Europa bekannt, einer Plattensystem-Plattform zur Behandlung... ► Artikel lesen | |
| STRYKER CORPORATION CDR Aktie jetzt für 0€ handeln | |||||
| 26.05. | Stryker launches Pangea plating system in Europe, reports first cases | 9 | MassDevice | ||
| 26.05. | Stryker Launches Pangea Plating System and Completes First Case in Europe | 391 | Business Wire | Stryker (NYSE:SYK), a global leader in medical technologies, announced today the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns.... ► Artikel lesen | |
| 20.05. | STRYKER CORP - 8-K, Current Report | 3 | SEC Filings | ||
| 20.05. | Stryker zahlte offenbar bis zu 835 Millionen Dollar für Gefäßspezialisten | 36 | ECOreporter | ||
| 19.05. | Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business | 520 | AFX News | WASHINGTON (dpa-AFX) - Tuesday, BioStar Capital announced that Amplitude Vascular Systems, Inc., a medical technology company, has been acquired by Stryker Corporation (SYK) at a purchase price... ► Artikel lesen | |
| 19.05. | Stryker buys Amplitude Vascular Systems for $835M | 6 | Seeking Alpha | ||
| 18.05. | Stryker enrolls first patient in first-in-human study of AVS IVL in a coronary indication | 5 | MassDevice | ||
| 16.05. | General Dynamics unit wins $229.65M Army deal for 50 Stryker A1 vehicles | 13 | Seeking Alpha | ||
| 12.05. | Argus cuts Stryker stock price target on cyberattack impact | 42 | Investing.com | ||
| 12.05. | Stryker deal to buy Amplitude Vascular Systems could reach up to $835M | 20 | MassDevice | ||
| 11.05. | STRYKER CORP - 10-Q, Quarterly Report | 35 | SEC Filings | ||
| 08.05. | Stryker: Aktionäre bestätigen Vorstand und Management-Vergütung auf Hauptversammlung | 38 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
187 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOCARDIA | 1,070 | +3,88 % | BioCardia Shares Surge 48% After FDA Feedback Supports Potential CardiAMP Approval Pathway |
Das Unternehmen STRYKER CORPORATION CDR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,300 (+2,50 %) liegt der Kurs bei 12,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu STRYKER CORPORATION CDR finden Sie auf Wallstreet Online.